641 related articles for article (PubMed ID: 26883434)
1. The fibrosis-cell death axis in heart failure.
Piek A; de Boer RA; Silljé HH
Heart Fail Rev; 2016 Mar; 21(2):199-211. PubMed ID: 26883434
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
[TBL] [Abstract][Full Text] [Related]
3. A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.
Frentzou GA; Drinkhill MJ; Turner NA; Ball SG; Ainscough JF
Dis Model Mech; 2015 Aug; 8(8):783-94. PubMed ID: 26092119
[TBL] [Abstract][Full Text] [Related]
4. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation.
Diwan A; Wansapura J; Syed FM; Matkovich SJ; Lorenz JN; Dorn GW
Circulation; 2008 Jan; 117(3):396-404. PubMed ID: 18178777
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocyte Hypertrophy in Arrhythmogenic Cardiomyopathy.
Gerçek M; Gerçek M; Kant S; Simsekyilmaz S; Kassner A; Milting H; Liehn EA; Leube RE; Krusche CA
Am J Pathol; 2017 Apr; 187(4):752-766. PubMed ID: 28183531
[TBL] [Abstract][Full Text] [Related]
6. Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling.
Chen Y; Wakili R; Xiao J; Wu CT; Luo X; Clauss S; Dawson K; Qi X; Naud P; Shi YF; Tardif JC; Kääb S; Dobrev D; Nattel S
J Mol Cell Cardiol; 2014 Dec; 77():113-24. PubMed ID: 25315712
[TBL] [Abstract][Full Text] [Related]
7. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
8. New directions in strategies using cell therapy for heart disease.
Itescu S; Schuster MD; Kocher AA
J Mol Med (Berl); 2003 May; 81(5):288-96. PubMed ID: 12698252
[TBL] [Abstract][Full Text] [Related]
9. Cardiomyocyte death and renewal in the normal and diseased heart.
Buja LM; Vela D
Cardiovasc Pathol; 2008; 17(6):349-74. PubMed ID: 18402842
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.
Sun B; Huo R; Sheng Y; Li Y; Xie X; Chen C; Liu HB; Li N; Li CB; Guo WT; Zhu JX; Yang BF; Dong DL
Hypertension; 2013 Feb; 61(2):352-60. PubMed ID: 23248151
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.
Travers JG; Kamal FA; Valiente-Alandi I; Nieman ML; Sargent MA; Lorenz JN; Molkentin JD; Blaxall BC
J Am Coll Cardiol; 2017 Aug; 70(8):958-971. PubMed ID: 28818206
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling.
Meagher PB; Lee XA; Lee J; Visram A; Friedberg MK; Connelly KA
Cells; 2021 Mar; 10(4):. PubMed ID: 33807373
[TBL] [Abstract][Full Text] [Related]
13. Functional disturbances due to structural remodeling in the failing human heart.
Hein S; Elsässer A; Kostin S; Zimmermann R; Schaper J
Arch Mal Coeur Vaiss; 2002 Sep; 95(9):815-20. PubMed ID: 12407797
[TBL] [Abstract][Full Text] [Related]
14. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
[TBL] [Abstract][Full Text] [Related]
15. Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium.
Zhang LX; Du J; Zhao YT; Wang J; Zhang S; Dubielecka PM; Wei L; Zhuang S; Qin G; Chin YE; Zhao TC
J Appl Physiol (1985); 2018 Dec; 125(6):1968-1978. PubMed ID: 30284520
[TBL] [Abstract][Full Text] [Related]
16. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
17. Anti-apoptosis in nonmyocytes and pro-autophagy in cardiomyocytes: two strategies against postinfarction heart failure through regulation of cell death/degeneration.
Takemura G; Kanamori H; Okada H; Miyazaki N; Watanabe T; Tsujimoto A; Goto K; Maruyama R; Fujiwara T; Fujiwara H
Heart Fail Rev; 2018 Sep; 23(5):759-772. PubMed ID: 29737434
[TBL] [Abstract][Full Text] [Related]
18. Role of apoptosis in remodeling after myocardial infarction.
Takemura G; Fujiwara H
Pharmacol Ther; 2004 Oct; 104(1):1-16. PubMed ID: 15500905
[TBL] [Abstract][Full Text] [Related]
19. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.
Oudit GY; Kassiri Z; Zhou J; Liu QC; Liu PP; Backx PH; Dawood F; Crackower MA; Scholey JW; Penninger JM
Cardiovasc Res; 2008 Jun; 78(3):505-14. PubMed ID: 18281373
[TBL] [Abstract][Full Text] [Related]
20. A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.
Schirone L; Forte M; Palmerio S; Yee D; Nocella C; Angelini F; Pagano F; Schiavon S; Bordin A; Carrizzo A; Vecchione C; Valenti V; Chimenti I; De Falco E; Sciarretta S; Frati G
Oxid Med Cell Longev; 2017; 2017():3920195. PubMed ID: 28751931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
